Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2021

Conditions
Sturge-Weber Syndrome
Interventions
DRUG

Cannabidiol

"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."

Trial Locations (1)

21205

Kennedy Krieger Institute, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

collaborator

Faneca 66 Foundation

OTHER

lead

Anne Comi, MD

OTHER